Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SARS-CoV-2 infection is causing a pandemic disease that is reflected in challenging public health problems worldwide. Human leukocyte antigen (HLA)-based epitope prediction and its association with disease outcomes provide an important base for treatment design. A bioinformatic prediction of T cell epitopes and their restricted HLA Class I and II alleles was performed to obtain immunogenic epitopes and HLA alleles from the spike protein of the severe acute respiratory syndrome coronavirus 2 virus. Also, a correlation with the predicted fatality rate of hospitalized patients in 28 states of Mexico was done. Here, we describe a set of 10 highly immunogenic epitopes, together with different HLA alleles that can efficiently present these epitopes to T cells. Most of these epitopes are located within the S1 subunit of the spike protein, suggesting that this area is highly immunogenic. A statistical negative correlation was found between the frequency of HLA-DRB1*01 and the fatality rate in hospitalized patients in Mexico.

Original publication

DOI

10.1002/jmv.26561

Type

Journal article

Journal

Journal of medical virology

Publication Date

04/2021

Volume

93

Pages

2029 - 2038

Addresses

Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, UNAM, Avenida de los Barrios 1, Tlalnepantla de Baz, Estado de México, Mexico.

Keywords

Humans, Epitopes, T-Lymphocyte, Hospitalization, Computational Biology, Antigen Presentation, Protein Structure, Tertiary, Mexico, Genetic Variation, HLA-DRB1 Chains, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2